Drugs Medical Pharma

Merck discontinues trial for combo cancer drug for melanoma

HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.

Read More
Drugs Medical Pharma

Moderna’s melanoma vaccine shows promise in clinical trials

HQ Team December 23, 2023: Moderna unveiled a skin cancer vaccine that demonstrated promising results in recent clinical trials. The vaccine, administered in.

Read More
Drugs Health Pharma

Novavax gets FDA nod for updated Covid-19 vaccine for 12 years and above

HQ Team October 4, 2023: The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12.

Read More
Drugs Health Pharma

CDC, ECDC differ on vaccination program for fall-winter season

HQ Team September 13, 2023: The US national public agency has recommended a COVID-19 vaccination policy where updated shots are given starting from.

Read More
Drugs Health Pharma

USFDA green lights vaccines to fight COVID-19 variants in flu season

HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and  BioNTech.

Read More
Drugs Health Pharma

Moderna, Immatics join hands to hunt for cancer therapies using mRNA, AI 

HQ Team September 11, 2023: Moderna Inc. announced a pact with Immatics NV, a clinical-stage biopharmaceutical company, to develop cancer therapies using a.

Read More
Drugs Health Medical Pharma

Cancer and cardio vaccines will be available by end 2030, says Moderna executive

HQ Team April 8, 2023: Cancer vaccines will be ready by the end of this decade, according to pharmaceutical company Moderna’s chief medical.

Read More
Drugs Pharma

Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designation 

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.

Read More
Drugs Pharma

Moderna in $35 million licensing deal with CytomX

Moderna, a US-based biotechnology company, announced a $35 million licensing deal with cancer-focused drugmaker CytomX to develop messenger RNA therapies.

Read More
Drugs Medical Pharma

Pfizer expected to charge quadruple for Covid vaccines in the US

Pfizer set to increase Covid-19 vaccine prices by almost four times in the US

Read More
X